Empagliflozin in Heart Failure Dialysis Patients

Shahid Beheshti University of Medical Sciences

Status: Completed

Conditions: Hemodialysis; Heart Failure

Treatments: Drug: Empagliflozin10Mg Tab

Study type: Interventional

Funder types: Other

Identifiers

NCT05967156

SBMU--

Details and patient eligibility

About

Empagliflozin is not still approved for glomerular filtration rate < 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Full description

Heart failure dialysis patients with residual renal function will be followed up on Empagliflozin based on echocardiographic parameters, pro-brain natriuretic peptide levels, diuresis volume, and serum acidity.

Enrollment: 30 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Heart failure on dialysis with residual renal function

Exclusion criteria

• Dialysis patients with no residual urine

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Empagliflozin

Experimental group

Description:

Heart failure dialysis patients will be treated with Empagliflozin

Treatment:

Drug: Empagliflozin10Mg Tab